Antegren: A Beacon of Hope, Chinese Version Harvard Case Solution & Analysis

The CEO of Biogen Idec confronts a set of tough choices regarding a promising drug for Multiple Sclerosis that's headed for early acceptance by the FDA. The first in a series, focuses on operational choices activated by the drive for early approval. Sparks discussion about a leader's economic, legal, and ethical duties to multiple constituencies, and how a leader can guide a business to perform efficiently, fulfilling those duties, in a situation that is complex.

Decisions facing the firm include how to secure insurance company compensation, and how to support credible research on the drug's effectiveness and safety, the way to increase production capacity to meet anticipated demand. All of these challenges appear against the backdrop of the accelerated approval process, uncertainty about what the FDA will ultimately determine, and whether the firm should really pursue early acceptance.

PUBLICATION DATE: November 14, 2007 PRODUCT #: 412C08-HCB-CHI

This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE

Antegren: A Beacon of Hope, Chinese Version Case Solution Other Similar Case Solutions like

Antegren: A Beacon of Hope, Chinese Version

Share This